The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax
John Allan, MD, Weill Cornell Medicine, New York, NY, discusses an update of the Phase II CAPTIVATE trial (NCT02910583) of ibrutinib plus venetoclax in front-line treated young patients with chronic lymphocytic leukemia (CLL). Dr Allan and his co-authors analyzed trial data of patients with high-risk features and found high rates of MRD-negativity following treatment, likely due to the disease being highly sensitive to this combination of agents in these individuals. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
